Cohort profile : Nordic Helicobacter Pylori eradication project (NordHePEP)
Pettersson, Anna-Klara; Santoni, Giola; Yan, Jacinth; Radkiewicz, Cecilia; Xie, Shaohua; Birgisson, Helgi; Ness-Jensen, Eivind; von Euler-Chelpin, My; Kauppila, Joonas H.; Lagergren, Jesper (2022-11-11)
Anna-Klara Pettersson, Giola Santoni, Jacinth Yan, Cecilia Radkiewicz, Shaohua Xie, Helgi Birgisson, Eivind Ness-Jensen, My von Euler-Chelpin, Joonas H. Kauppila & Jesper Lagergren (2023) Cohort profile: Nordic Helicobacter Pylori eradication project (NordHePEP), Scandinavian Journal of Gastroenterology, 58:5, 453-459, DOI: 10.1080/00365521.2022.2144435
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
https://creativecommons.org/licenses/by-nc-nd/4.0/
https://urn.fi/URN:NBN:fi-fe2023070585032
Tiivistelmä
Abstract
Purpose: This cohort description presents the Nordic Helicobacter Pylori Eradication Project (NordHePEP), a population-based cohort of patients having received eradication treatment for Helicobacter pylori (HP). The cohort is created with the main purpose of examining whether and to what extent HP eradication treatment influences the risk of gastrointestinal cancer.
Participants: NordHePEP includes all adults (aged ≥18 years) having been prescribed and dispensed HP eradication treatment according to the nationwide complete drug registries in any of the five Nordic countries (Denmark, Finland, Iceland, Norway, or Sweden) between 1994 and 2020 (start and end year varies between countries). We have retrieved and merged individual-level data from multiple national registries, including drug, patient, cancer, population, and death registries.
Findings: The cohort includes 674,771 patients having received HP eradication treatment. During up to 23 years of follow-up, 59,292 (8.8%) participants were diagnosed with cancer (non-melanoma skin cancer excluded), whereof 15,496 (2.3%) in the gastrointestinal tract.
Future plans: We will analyse HP eradication treatment in relation to gastrointestinal cancer risk. Standardised incidence ratios will be calculated as the observed cancer incidence in the cohort divided by the expected cancer incidence, derived from the background population of the corresponding age, sex, and calendar year.
Kokoelmat
- Avoin saatavuus [38865]
